For this year’s Sourcebook, the Clarivate analysis included a fourth therapeutic area: immunology and immune disorders. This therapeutic area records numbers of trials initiated on a par with the cardiovascular and metabolic diseases. The UK is competitive as a site for immunology and immune disorders clinical research, very closely tracking Poland. However, Germany is consistently recording more trials than any other country other than the US. Again, 2016 suggests a break in the data series, although it could be a temporary variation. As in the case of the oncology trials, the US is differentiated not only by the overall number of trials it hosts but in the increase in that number in 2016, in contrast to most other countries in the peer group assessment (excepting Australia and Italy which also showed a slight increase).
Data was collected from Cortellis Clinical Trial Intelligence, Clarivate Analytics using the following criteria: trial start date (1st January 2012 – 31st December 2016), phase (I, II, III), and country (UK, Spain, Germany, France, Italy, Poland, USA, Canada, Australia, and Japan). Only trials related to pharmaceutical drug development and molecular/biological entities were included. Only commercial trials were included. Collaborative trials were only included if one or more partners were a commercial organisation. All therapeutic areas were included in this analysis. This analysis focused on immunology trials only. Trials across multiple therapy areas were only included once. The therapy area in which they were included was determined by the trial’s main purpose for study.